Bearish
Johnson & Johnson's Q3 profit plunges 96% due to talc litigation charges
Johnson & Johnson reported a 96% decline in net earnings for Q3 2026, primarily due to a one-time special charge related to talc litigation. Despite this, the company raised its full-year sales and adjusted earnings guidance, indicating strong operational performance.
Key points
- Net earnings fell 96% to $210 million, or $0.09 per share, from $5.15 billion, or $2.12 per share, a year earlier, mainly due to a one-time special charge related to the proposed talc litigation resolution.
- Sales increased by 5.9% year-over-year to $25.4 billion, with the Innovative Medicine division contributing significantly to this growth.
- The company announced a quarterly dividend of $1.34 per share for Q4 2026, payable on December 8, 2026.
- Johnson & Johnson raised its full-year 2026 adjusted earnings per share guidance to $11.10 and estimated reported sales to $101.2 billion, reflecting strong operational performance.
Sources
- Johnson & Johnson Stock Falls 5% After Q3 Profit PlungesRTTNews · October 13, 2026
- Johnson & Johnson reports Q3 2026 results, raises 2026 guidanceBusiness Wire · October 13, 2026
- Johnson & Johnson Announces Quarterly Dividend for Fourth Quarter 2026Business Wire · October 13, 2026
- Johnson & Johnson Q3 Profit Plunges, Lifts FY26 Outlook; Stock DropsRTTNews · October 13, 2026
AI-generated from public news sources. Not financial advice.
